2024-08-29 14:25:00
More than 1 in 10 people are affected by migraines. Currently, although basic and crisis treatments are available (anti-inflammatory drugs, triptans, anti-epileptic drugs, antidepressants, beta-blockers, etc.), they are not effective for all migraine patients and may have significant adverse reactions and contraindications. “ Many patients do not respond to treatmentwe really don’t know what to do,” neuroscientist Dr. Bruno Perrouty lamented. Therefore, finding new therapeutic approaches among therapeutic modalities is a major challenge.
A treatment called Ubrelvy (ubrogepant) is new class of drugs : Oral antagonists of CGRP receptors, better known as “gepants”. Due to the positive results of clinical trials conducted in more than 70 specialized centers, it has been Authorized in the United States in 2019. A study published in the journal on August 28, 2024 once again demonstrated its effectiveness Neurology (Source 1).
Stop migraine symptoms as soon as they occur
This innovative treatment method allows Take it to prevent headaches when you have migraine symptoms. A migraine attack is often preceded by early symptoms such as sensitivity to light and noise, fatigue, dizziness, and even neck stiffness.
The study compared the effects of ubrogepant with placebo in adults with migraine. When warning signs of migraine occur, they are asked to receive treatment and monitor symptoms and their impact on activity. As a result, “researchers found that as early as two hours after taking the drug, people who took the drug 73% more likely to say they have “no disability”They were able to function “more normally than those who took a placebo,” according to the press release. As a result, patients who received ubrogepant had fewer restrictions in their activities soon after taking the drug and over time than patients who received placebo.
“Based on our results, treatment with ubrogepant could allow migraine patients who experience warning signs before a migraine attack to be treated quickly in the early stages of a migraine attack and continue with their daily lives with little discomfort and disruption. Our results are encouraging“Because they think ubrogepant could help migraine patients return to normal function,” said study author Dr. Richard B. Lipton, of the Albert Einstein College of Medicine in the Bronx, New York, and a member of the American Society. and carry out daily activities.
Has many advantages over existing treatments
According to a review of research published in 2023 (Source 3), “ubrogépant has become a Potential breakthrough drug for migraine treatment ”. And for good reason: In addition to being effective and quickly relieving pain, the treatment is also well tolerated. The patient actually suffers from Few side effects. Additionally, it is a non-narcotic treatment, so unlike some painkillers, there is no risk of dependence and overconsumption. Finally, unlike triptans, which are widely used in migraine patients, ubrogepant does not carry cardiovascular risks.
This treatment has not yet been approved in France. However, other drugs in this class of treatments are available, but they are not No refund. “All these products with good efficacy, even very effective in some particularly sensitive patients, are not reimbursed. This is what slows down the implementation of these treatments in France. According to him, “Currently these treatments are considered More effective than trypsin would be. Very interesting treatment optionbut was blocked due to non-reimbursement.
1724954526
#drug #stop #migraines #symptoms
